Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours

BACKGROUND: Treatment options for patients with metastatic gastroenteropancreatic neuroendocrine tumours (GEP NETs) are still limited. We investigated the antitumour activity and safety profile of pazopanib – a multitarget drug with anti-angiogenic activity in patients with metastatic GEP NETs. METH...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahn, H K, Choi, J Y, Kim, K-M, Kim, H, Choi, S-H, Park, S H, Park, J O, Lim, H Y, Kang, W K, Lee, J, Park, Y S
Format: Artigo
Language:Inglês
Published: Nature Publishing Group 2013
Subjects:
Clinical Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3776983/
https://ncbi.nlm.nih.gov/pubmed/23989950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.470
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items